Colon News and Research

RSS

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

First case of treating cystic fibrosis and Crohn's disease with infliximab

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

20 Apr 2010

UAB researchers discover four miRNAs to assess survival rate of colorectal cancer patients

Researchers at the University of Alabama at Birmingham Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Biomarkers to help predict development of aggressive colorectal cancer discovered

Researchers at the University of Alabama at Birmingham (UAB) Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Study reveals increased risk for cancer among Latino populations

New findings from epidemiology and observational studies show an increased risk for cancer among Latino populations, but unique demographic characteristics suggest the problem may be worse than currently known.

19 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Exclusive licensing practices slows innovation in gene testing market

Exclusive licenses to gene patents, most of which are held by academic institutions and based on taxpayer-funded research, do more to block competition in the gene testing market than to spur the development of new technologies for gauging disease risk, say researchers at the Duke Institute for Genome Sciences & Policy (IGSP).

15 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

Florida to enact health care legislation to improve access to ARV therapy

Florida is poised to enact health care legislation that would add clarity to existing state statutes by requiring that all state-regulated health plans include lifesaving antiretroviral (ARV) HIV/AIDS drugs on their drug formularies or preferred drug lists.

15 Apr 2010

Inflammasome components help protect against colitis

Particular components of inflammasomes-protein complexes needed for generating immune responses to pathogens and cellular damage-lessen the severity of colitis and colitis-associated colon cancer in mice, according to a study published online this week in the Journal of Experimental Medicine.

13 Apr 2010

National organizations, medical institutions join Lung Cancer Alliance to address nation's most lethal cancer

Today, Lung Cancer Alliance announced new additions to the growing list of supporters joining LCA in its "call to action" to devise a better public health strategy to address the nation's most lethal cancer.

13 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Modified ESD procedure can remove large ileal lipoma: Research article

Lipoma is relatively common in the colon but is less often in the small intestine. Most lipomas are incidentally detected at endoscopy and are usually small and asymptomatic. However, some of them can present with obstruction and/or intussusceptions. Surgical resection is commonly recommended to remove such significant lipomas with a limited pedicle and larger than 2 cm in size, as endoscopic resection may result in unfavorable complications such as intestinal perforations.

12 Apr 2010

Recql5 identified as a tumor suppressor in GI tract

Recql5 is a member of the mammalian RecQ helicase family. Genetic mutations that result in loss of RecQ helicase activity give rise to disorders that are associated with cancer predisposition and premature aging, such as Bloom, Werner, and Rothmund-Thomson syndromes. This class of enzymes is best known for their role in maintaining the integrity of the genome to prevent oncogenic mutations.

9 Apr 2010